報價延遲最少15分鐘:2026/05/06 12:47 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
-- 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.03/-1.69
|
|
企業價值
6.12B
|
| 資產負債 |
|
每股賬面淨值
8.71
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of chronic disease. The company's oncology asset is TERN-701, a novel, oral allosteric BCR-ABL1 inhibitor for CML currently in Phase 1/2 development. The company's legacy metabolic programs include TERN-501, a clinical-stage thyroid hormone receptor-Beta for MASH and/or obesity, and TERN-801, a glucose-dependent insulinotropic polypeptide receptor antagonist development candidate for obesity. The company is seeking strategic partners to advance the TERN-501 and TERN-801 programs. |
